This is a Phase I, single-arm, open-label, dose-escalation, multicenter clinical study of CS231295 in patients with advanced solid malignant tumors. Eligible …

Advance Solid TumorsAdvanced Malignant Solid Tumors

~Estimated

~$10 – $8,750

ThalassaX Therapeutics United States LtdNCT07612488

Phase 1

A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participan…

Advance Solid Tumors

~Estimated

~$10 – $8,750

Kivu Bioscience Inc.NCT07229313